Financings in Brief: Vysis
This article was originally published in The Gray Sheet
Executive Summary
Vysis: Initial public offering Feb. 5 nets about $33.5 mil. The genetic test and disease management firm's IPO consisted of 3 mil. shares of common stock at $12 per share. Initial plans for the offering, announced in October, called for a slightly larger offering of 3.5 mil. shares ("The Gray Sheet" Nov. 3, I&W-5). The Downers Grove, Illinois-based firm plans to use a portion of the proceeds for expansion of direct sales and marketing capabilities. Underwriters Furman Selz, Deutsche Morgan Grenfell and Everen Securities hold an overallotment option for up to 450,000 additional shares...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.